Linear regression for annualised SC atrophy rate over 24 months, adjusted for centre
| Univariate | Multivariate | |||||
|---|---|---|---|---|---|---|
| Coefficient b | SE | p Value | Coefficient b | SE | p Value | |
| Clinical parameters | ||||||
| Centre* (A vs B) | 0.67 | 0.28 | 0.02 | 0.41 | 0.28 | 0.14 |
| Gender (male vs female) | −0.35 | 0.29 | 0.23 | |||
| MS subtype (RR=1; PP and SP=0)* | 0.85 | 0.31 | <0.01 | 0.59 | 0.34 | 0.08 |
| Age* | −0.01 | 0.01 | 0.51 | – | – | – |
| Disease duration* | −0.03 | 0.02 | 0.04 | −0.06 | 0.02 | 0.003 |
| Use of DMT* | −0.04 | 0.28 | 0.89 | – | – | – |
| EDSS baseline | −0.11 | 0.09 | 0.23 | |||
| MRI parameters | ||||||
| NGMV baseline* | 0.004 | 0.002 | 0.09 | – | – | – |
| NWMV baseline | −0.004 | 0.003 | 0.16 | |||
| NBV baseline | 0.001 | 0.002 | 0.73 | |||
| T2LV baseline† * | −0.14 | 0.09 | 0.13 | – | – | – |
| T1LV baseline† | −0.08 | 0.07 | 0.23 | |||
| Presence of Gd+ brain lesions at baseline | 0.03 | 0.39 | 0.94 | |||
| Number of SC segments† * | −0.44 | 0.19 | 0.03 | −0.49 | 0.19 | 0.01 |
| Number of SC lesions† | −0.33 | 0.18 | 0.08 | |||
| UCCA baseline* | −0.04 | 0.01 | 0.002 | −0.06 | 0.02 | <0.001 |
| Diffuse SC abnormalities baseline (0=absent; 1=present)* | −0.52 | 0.44 | 0.23 | −0.96 | 0.42 | 0.02 |
| Δ T2 LV (0–24 month)† | 0.69 | 0.44 | 0.12 | |||
| aPBVC (0–24 month)* | 0.56 | 0.24 | 0.02 | – | – | – |
| Δ T1 LV (0–24 month)† * | −1.29 | 0.66 | 0.05 | −1.4 | 0.7 | 0.04 |
Models were statistically adjusted for centre. The model accounts for 238 patients with MS (68%) with all parameters available. R2 of the model was 0.14.
*Independent variables that were initially entered in the multivariate model.
†Data were obtained with natural log transformation.
aPBVC, annualised percentage brain volume change; Centre A, Amsterdam, Centre B, Basel; DMT, disease modifying therapy; EDSS, expanded disability status scale; Gd+: gadolinium enhancing; MS, multiple sclerosis; NBV: brain volume normalised for head size; NGMV, normalised grey matter volume; NWMV: normalised white matter volume; PPMS: primary progressive MS; RRMS, relapsing remitting MS; SC: spinal cord; SPMS: secondary progressive MS; T2LV: volume of T2 brain lesion; T1LV: volume of T1 hypointense brain lesion; UCCA: mean upper cervical cord cross-sectional area.